NAMS
The table below shows NewAmsterdam Pharma Company N.V.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $22.50M | $45.56M | $14.09M | $102.69M | - |
| Cost of revenue | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| R&D | $141.83M | $151.41M | $159.42M | $86.74M | $28.97M |
| SG&A | $106.35M | $70.45M | $37.63M | $19.51M | $6.00M |
NewAmsterdam Pharma Company N.V. reported annual revenue of $22.50M for fiscal year 2025. That is down 50.6% from $45.56M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$225.68M |
| -$176.29M |
| -$182.97M |
| -$3.56M |
| -$34.98M |
| Income tax | - | -$1.00K | $27.00K | - | - |
| Net income | -$203.00M | -$242.00M | -$177.00M | -$22.63M | -$41.78M |
| EPS (diluted) | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 |